Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the effect of two dose levels of MORAb-003 or placebo in combination with carboplatin and taxane on progression-free survival (PFS), as determined by RECIST, in subjects with platinum-sensitive ovarian cancer in first relapse.
Critère d'inclusion
- First relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies